Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ivarmacitinib - Arcutis Biotherapeutics/Reistone Biopharma

Drug Profile

Ivarmacitinib - Arcutis Biotherapeutics/Reistone Biopharma

Alternative Names: ARQ 252 active ingredient - Jiangsu Hengrui Medicine; Ivarmacitinib sulfate - Arcutis Biotherapeutics/Reistone Biopharma; SHR-0302; SHR0302 base

Latest Information Update: 25 Jul 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Jiangsu Hengrui Medicine Co.
  • Developer Jiangsu Hengrui Medicine Co.; Reistone Biopharma
  • Class 2 ring heterocyclic compounds; Amides; Amines; Anti-inflammatories; Antirheumatics; Cyclopentanes; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules; Thiadiazoles
  • Mechanism of Action Janus kinase 1 inhibitors; STAT3 transcription factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Atopic dermatitis; Psoriatic arthritis; Rheumatoid arthritis; Ulcerative colitis
  • Phase II/III Ankylosing spondylitis; Vitiligo
  • Phase II Alopecia areata; Crohn's disease
  • Phase I Liver disorders
  • Research Systemic lupus erythematosus

Most Recent Events

  • 15 Jul 2022 Phase-I drug-drug interaction trial in Rheumatoid arthritis (In volunteers) in China (PO) (NCT05392127)
  • 08 Jun 2022 Jiangsu HengRui Medicine completes a phase I drug interaction trial in Healthy volunteers, In China (NCT05047341)
  • 07 Jun 2022 Jiangsu HengRui Medicine plans a pharmacokinetic phase I trial in Rheumatoid arthritis (In volunteers, Combination therapy, Monotherapy) (PO, Tablet), in June 2022 (NCT05404724)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top